Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a positive outlook with significant improvements in net income, cash reserves, and strategic expansions in treatment centers. The Q&A section reveals some uncertainties, particularly around QTC ramp-up and profitability timelines, but overall market access and reimbursement are strong. The recent FDA approval and commercial transition bolster sentiment, while the gain from the priority review voucher sale is a financial positive. The positive indicators outweigh the uncertainties, suggesting a likely stock price increase.
Key Financial Performance
Total Revenue for 2025 $5.8 million, which includes $3.4 million in license and other revenues and $2.4 million in net product revenue. The license and other revenues were primarily driven by a $3 million clinical milestone achieved in Q4 2025 under a sublicense agreement for Rett syndrome with Taysha Gene Therapies. The net product revenue reflects the patient treatment in December.
Cost of Sales for 2025 $1.5 million, primarily driven by the first commercial ZEVASKYN treatment in December and costs from the August production batch that was not released due to technical challenges related to an FDA-mandated rapid sterility lot release assay.
R&D Spending for 2025 $26.8 million, a decrease of $7.6 million compared to $34.4 million in 2024. This reduction was primarily driven by the April 2025 FDA approval of ZEVASKYN, which resulted in certain production costs being capitalized into inventory and engineering runs no longer classified as R&D expenses.
SG&A Expenses for 2025 $65 million, an increase of $35.1 million over 2024. This increase primarily reflects Abeona's commercial transition following the April 2025 FDA approval of ZEVASKYN, including $18.6 million in personnel and stock-based compensation and $2.3 million in direct commercialization costs. Additionally, certain engineering and training expenses previously classified as R&D were transitioned to SG&A post-approval.
Gain on Sale of Priority Review Voucher $152.4 million, recorded after selling the rare pediatric disease priority review voucher awarded following the FDA approval of ZEVASKYN in May 2025. Payment was received in June 2025.
Net Income for 2025 $71.2 million, or $0.34 per basic and $1.01 per diluted common share. This is a significant improvement compared to a net loss of $63.7 million in 2024.
Cash Equivalents and Short-term Investments as of December 31, 2025 $191.4 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ZEVASKYN launch: ZEVASKYN, the first autologous cell-based gene therapy for RDEB, was approved in April 2025. The launch was delayed to Q4 2025 due to sterility test optimization. The first commercial patient was treated in December 2025, and the company is ramping up launch execution in 2026.
Patient treatments and biopsies: Since resuming manufacturing in January 2026, one patient has been treated, three biopsied, and additional biopsies are scheduled. Treatments and biopsies are currently from two qualified treatment centers (QTCs), with two more QTCs preparing to schedule patients.
Market demand and access: Demand for ZEVASKYN has grown, with over 100 eligible patients identified. All major commercial payers and Medicaid programs in all 50 states have coverage policies for ZEVASKYN. A permanent HCPCS J-code was established effective January 1, 2026, to streamline billing and reimbursement.
Expansion of treatment centers: Four QTCs are currently activated, with two treating patients and two in the administrative process. The company aims to onboard five additional centers, targeting seven active QTCs by the end of 2026.
Operational efficiency: The company is focused on building a consistent cadence of biopsies, product delivery, and treatments. Efforts are being made to ensure a seamless patient experience and operational excellence to scale ZEVASKYN.
Financial performance and strategy: Total revenue for 2025 was $5.8 million, with $3.4 million from license revenues and $2.4 million from product revenue. The company recorded a $152.4 million gain from selling a rare pediatric disease priority review voucher. Net income for 2025 was $71.2 million, and cash equivalents totaled $191.4 million as of December 31, 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Launch Delays: The launch of ZEVASKYN was delayed to Q4 2025 due to the need to optimize a sterility test required for product release, which could impact revenue and market momentum.
Patient Treatment Speed: The speed at which identified patients receive ZEVASKYN treatment has significantly varied, potentially affecting the scaling and operational efficiency of the treatment process.
QTC Onboarding Challenges: Becoming a Qualified Treatment Center (QTC) is a multi-step, several-month process involving multiple approvals and protocols, which could delay the expansion of treatment availability.
Production Costs and Technical Challenges: Production costs remain high, and technical challenges related to an FDA-mandated rapid sterility lot release assay have previously impacted product availability.
Administrative Process Delays: Patients advancing through the administrative process for treatment face delays, which could hinder timely access to ZEVASKYN and affect patient satisfaction.
Revenue Dependence on Payer Mix: Current revenue is heavily influenced by Medicaid patients, and normalization of net revenues depends on expanding the payer mix to include more commercially insured patients.
Operational Scaling Risks: Ensuring a seamless patient experience and operational excellence is critical for scaling ZEVASKYN, and any missteps could impact demand and reputation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ZEVASKYN patient treatment and biopsy projections: The company expects to perform additional biopsies this month and anticipates a healthy cadence of patient biopsies in the coming months. They also expect the number of ZEVASKYN treatments to grow in the coming quarters as more QTCs treat patients and gain experience.
Expansion of Qualified Treatment Centers (QTCs): The company aims to have at least 7 QTCs active by the end of 2026, up from the current 4 QTCs. They are actively working toward onboarding 5 additional centers.
Market access and reimbursement: ZEVASKYN has coverage policies from major commercial payers representing roughly 80% of commercially covered lives and baseline coverage across all Medicaid programs in all 50 states. CMS has established a permanent HCPCS J-code for ZEVASKYN effective January 1, 2026, which is expected to streamline billing and reimbursement for QTCs.
Revenue and gross margin expectations: The company expects average net revenues to normalize over time as the payer mix expands to include commercially insured patients. Gross margins are expected to increase significantly with better economies of scale related to production costs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the cadence for onboarding qualified treatment centers (QTCs) and factors influencing their speed?
A:The company is working with 5 centers, with one imminent and aiming for 7 active by year-end. Factors influencing speed include ZEVASKYN approval, payer mix, institutional bureaucracies, and cross-functional interactions. The company has learned from onboarding previous centers and aims to streamline the process.
Q:What are the drivers of R&D spending for 2026 and beyond?
A:R&D spending will be driven by the registry study required by the FDA, pipeline development costs, and a shift from R&D to SG&A as the company transitions to a commercial entity. Preclinical programs are not expected to significantly impact R&D expenses in 2026, but this may change in 2027 depending on ZEVASKYN's ramp-up.
Q:What is the expected patient distribution among QTCs?
A:The company expects a decent pool of patients at each QTC. Their strategy includes placing patients in QTCs, focusing on community physician referrals, and geographically spreading centers to improve access and reduce payer barriers.
Q:What is the expected patient capacity per QTC?
A:Currently, QTCs can manage 1-2 patients per month, with some potentially increasing to 3 patients per month depending on resources and experience. The company expects this to improve over time.
Q:What is the timeline from receipt of start form to treatment initiation?
A:The timeline is variable, averaging 4-5 months, including 25 days for manufacturing. This is expected to improve as administrative processes become more efficient.
Q:How confident is the company in achieving profitability in the first half of the year?
A:The company believes achieving profitability is reasonable, requiring 3.5 or more patients per month to reach the profitable zone. Variables include the speed of QTC ramp-up and onboarding additional sites.
Q:Has the target number of QTCs increased?
A:The target remains 5-7 QTCs, with 7 being a realistic goal for this year. Additional centers may spill over into next year due to lengthy onboarding processes.
Q:What is the status of reimbursement and pre-authorization processes?
A:Reimbursement is guided by inclusion/exclusion criteria, but letters of medical necessity can overturn restrictions. The process is improving as templates and administrative steps are streamlined.
Q:What is the current manufacturing capacity and plans for expansion?
A:The company is currently running at 6 patients per month and plans to increase to 10 patients per month by the second half of the year. Sterility testing issues have been resolved, and further improvements are ongoing.
Q:What feedback has been received from patients and physicians?
A:Feedback is limited as only two patients have been treated. Physicians report patients are doing well, but it is too early to assess outcomes.
Q:Are there any exclusions for retreatment of patients?
A:There are no exclusions for retreatment. Payers are not blocking retreatment, and policies allow for multiple treatments if needed.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on the following: 1. Specific evidence-based cadence for QTC ramp-up, as projections are based on preliminary data. 2. Detailed feedback from patients and physicians, as it is too early to assess outcomes. 3. Exact timeline for achieving profitability, as it depends on multiple variables.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aetna Blue
CEO CFO
CFO institution
CMS HCPCS
Colorado UTMB
Conference conference
Cost sale
Demand ZEVASKYN
Dr Chief
Dr update
EB specialist
Officer Chief
RD
SGA
Securities
addition
approval ZEVASKYN
biopsy QTCs
biopsy month
biopsy treatment
cadence biopsy
code
community physician
coverage
delivery
demand ZEVASKYN
engineering
launch momentum
milestone
number ZEVASKYN
patient biopsy
patient process
payment
process biopsy
revenue
scale
speed
sterility
training
treatment Cost
treatment biopsy
treatment patient
treatment week
ABEO Transcript
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
Unknown5-13
Due to the absence of explicit financial details or strategic updates in the earnings call summary and Q&A session, there's insufficient evidence to predict significant stock movement. The lack of clarity or new information suggests a neutral market reaction, as there's no catalyst for significant positive or negative sentiment.
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
Positive3-17
The earnings call presents a positive outlook with significant improvements in net income, cash reserves, and strategic expansions in treatment centers. The Q&A section reveals some uncertainties, particularly around QTC ramp-up and profitability timelines, but overall market access and reimbursement are strong. The recent FDA approval and commercial transition bolster sentiment, while the gain from the priority review voucher sale is a financial positive. The positive indicators outweigh the uncertainties, suggesting a likely stock price increase.
Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call presents a positive outlook with reduced net loss, progress in market access, and strategic expansion plans. The Q&A section confirms no significant impact on profitability timelines despite delays, maintaining a positive sentiment. The company's progress in securing insurance coverage and expanding treatment centers suggests strong future growth potential. Despite some uncertainties in patient timelines and QTC partnerships, overall sentiment remains positive, supported by optimistic guidance and a clear path to profitability by 2026. The absence of a market cap suggests a neutral to positive reaction, likely around 2% to 8%.
Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript
Positive8-19
The earnings call indicates strong financial performance with a significant increase in net income driven by strategic asset sales. The Q&A section reveals positive developments, including successful patient advocacy, strong demand for ZEVASKYN, and effective partnerships. Despite some uncertainties in management responses, the overall sentiment is positive, with optimistic guidance and plans for expansion. The company's ability to meet production goals and achieve profitability in the near future further supports a positive stock price movement.
ABEO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
